{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:27Z","timestamp":1791181287473,"version":"4.1.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"sup113","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scandinavian Journal of Rheumatology"],"published-print":{"date-parts":[[2000,1]]},"DOI":"10.1080\/030097400446625","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T15:47:33Z","timestamp":1027698453000},"page":"37-45","source":"Crossref","is-referenced-by-count":87,"title":["Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists"],"prefix":"10.1080","volume":"29","author":[{"given":"H.","family":"Wolf","sequence":"first","affiliation":[{"name":"Novartis Pharma GmbH, Deutschherrnstrasse 15, DE-90327 Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,7,12]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"crossref","unstructured":"Gaddum JH Picarelli ZP. Two kinds of tryptamine receptors. Br J Pharmacol 1957; 12 :323\u2013 8.","DOI":"10.1111\/j.1476-5381.1957.tb00142.x"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","unstructured":"Fozard JR Ali AT. Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart. Naunyn Schmiede-bergs Arch Pharmacol 1978; 301 :223\u2013 5.","DOI":"10.1007\/BF00507041"},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","unstructured":"Bradley PB Engel G Feniuk W Fozard JR et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol 1986; 25 :563\u2013 76.","DOI":"10.1016\/0028-3908(86)90207-8"},{"key":"e_1_2_1_5_1","unstructured":"Hoyer D Clarke DE Fozard JR et al. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157 \u2014 203."},{"key":"e_1_2_1_6_1","doi-asserted-by":"crossref","unstructured":"Boess FJ Beroukhim R Martin IL. Ultrastructure of the 5-hydroxytryptamine3 receptor. J Neurochem 1995; 64: 1401\u2013 5.","DOI":"10.1046\/j.1471-4159.1995.64031401.x"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","unstructured":"Tecott LH Maricq AV Julius D. Nervous system distribution of the serotonin 5-HT3 receptor mRNA. Proc Natl Acad Sci 1993; 90: 1430\u2013 4.","DOI":"10.1073\/pnas.90.4.1430"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","unstructured":"Greenshaw AJ Silverstone PH. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Drugs 1997; 53 :20\u2013 39.","DOI":"10.2165\/00003495-199753010-00003"},{"key":"e_1_2_1_9_1","unstructured":"Hoyer D. Serotonin 5-HT3 5-HT4 and 5-HT-M-receptors. Neuropsychopharmacology 1990; 3 :371\u2013 83."},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","unstructured":"Miller RC Galvan M Gittos MW et al. Pharmacologicalproperties of dolasetron a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 1993; 28 :87\u2013 93.","DOI":"10.1002\/ddr.430280111"},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","unstructured":"Newberry NR Watkins CJ Sprosen TS et al. BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 1993; 32 :729\u2013 35.","DOI":"10.1016\/0028-3908(93)90180-B"},{"key":"e_1_2_1_12_1","doi-asserted-by":"crossref","unstructured":"Gebauer A Merger M Kilbinger H. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 347: 137\u2013 40.","DOI":"10.1007\/BF00169258"},{"key":"e_1_2_1_13_1","unstructured":"Fischer V Vickers AEM Heitz F et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists tropisetron and ondanse-tron. Drug Metab Dispos 1994; 22 :269\u2013 74."},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","unstructured":"Balfour JA Goa KL. Dolasetron. Drugs 1997; 54 :273\u2013 98.","DOI":"10.2165\/00003495-199754020-00008"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","unstructured":"Bloomer JC Baldwin SJ Smith GJ et al. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994; 38 :557\u2013 66.","DOI":"10.1111\/j.1365-2125.1994.tb04397.x"},{"key":"e_1_2_1_16_1","unstructured":"Sanwald P David M Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Drug Metab Dispos 1996; 24: 602\u2013 9."},{"key":"e_1_2_1_17_1","unstructured":"Blackwell CP Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25 :S21\u2013 4."},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","unstructured":"Plosker GL Goa KL. Granisetron. Drugs 1991; 42 :805\u2013 24.","DOI":"10.2165\/00003495-199142050-00007"},{"key":"e_1_2_1_19_1","unstructured":"Navoban Produktmonografie Novartis Pharma GmbH Nuremberg 1996."},{"key":"e_1_2_1_20_1","unstructured":"Cubeddu LX. Mechanisms by which cancer chemotherapy drugs induce emesis. Sem Oncol 1992; 19 Suppl 15:2\u2013 13."},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","unstructured":"Toni Y Mutoh M Saito H Matsuki N. Involvement of free radicals in cisplatin-induced emesis in Suncus murinus. Eur J Pharmacol 1993; 248 :131\u2013 5.","DOI":"10.1016\/0926-6917(93)90034-N"},{"key":"e_1_2_1_22_1","doi-asserted-by":"crossref","unstructured":"Jantunen IT Kataja VV Muhonen TT. An overview of randomixed studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemo-therapy-induced vomiting. Eur J Cancer 1997; 33: 66\u2013 74.","DOI":"10.1016\/S0959-8049(96)00276-6"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","unstructured":"Tavorath R Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996; 52 :639\u2013 48.","DOI":"10.2165\/00003495-199652050-00002"},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","unstructured":"Antiemetic subcommittee of the MASCC: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998; 9 : 811\u2013 9.","DOI":"10.1023\/A:1008471812316"},{"key":"e_1_2_1_25_1","doi-asserted-by":"crossref","unstructured":"Drechsler S Bruntsch U Eggert J et al. Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Supp Care Cancer 1997; 5 :387\u2013 95.","DOI":"10.1007\/s005200050097"},{"key":"e_1_2_1_26_1","doi-asserted-by":"crossref","unstructured":"Scarantino CW Ornitz RD Hoffman LG et al. On the mechanism of radiation-induced emesis: the role of serotonin. Int J Radiat Oncol Biol Phys 1994; 30 :825\u2013 30.","DOI":"10.1016\/0360-3016(94)90356-5"},{"key":"e_1_2_1_27_1","unstructured":"Feyer P Zimmermann JS Titlbach OJ et al. Radiotherapy-induced emesis. An overview. Strahlenther Onkol (1998); 174 Suppl 3:56\u2013 61."},{"key":"e_1_2_1_28_1","doi-asserted-by":"crossref","unstructured":"Franzen L Nyman J Hagberg H et al. A randomised placebo controlled study with ondansetron in patients under-going fractionated radiotherapy. Ann Oncol 1996; 7 :587\u2013 92.","DOI":"10.1093\/oxfordjournals.annonc.a010675"},{"key":"e_1_2_1_29_1","doi-asserted-by":"crossref","unstructured":"Biebuyck JF. Postoperative nausea and vomiting. Anesthe-siology 1992; 77 :162\u2013 84.","DOI":"10.1097\/00000542-199207000-00023"},{"key":"e_1_2_1_30_1","doi-asserted-by":"crossref","unstructured":"Alon E Biro P. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockade]. Ana-sthesiol Intensivmed Notfallmed Schmerzther 1996; 31 :200\u2013 4.","DOI":"10.1055\/s-2007-995902"},{"key":"e_1_2_1_31_1","doi-asserted-by":"crossref","unstructured":"Gregory RE Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998; 55 :173\u2013 89.","DOI":"10.2165\/00003495-199855020-00002"},{"key":"e_1_2_1_32_1","unstructured":"Schw\u00f6rer H Munke H Stockmann F et al. Treatment of diarrhea in carcinoid syndrome with ondansetron tropisetron and clonidine. Am J Gastroenterol 1995; 90 :645\u2013 8."},{"key":"e_1_2_1_33_1","doi-asserted-by":"crossref","unstructured":"Lecrubier V Puech AJ Azcona A et al. A randomiseddouble-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1993; 112 :129\u2013 33.","DOI":"10.1007\/BF02247373"},{"key":"e_1_2_1_34_1","doi-asserted-by":"crossref","unstructured":"Zoldan J Griedberg G Livneh M et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron a 5-HT3 receptor antagonist. Neurology 1995; 45 :1305\u2013 8.","DOI":"10.1212\/WNL.45.7.1305"},{"key":"e_1_2_1_35_1","doi-asserted-by":"crossref","unstructured":"Sellers EM Toneatto T Romach MK et al. Clinicla efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol 1994; 18 :879\u2013 85.","DOI":"10.1111\/j.1530-0277.1994.tb00054.x"},{"key":"e_1_2_1_36_1","unstructured":"Preston GC 5-HT3 antagonists and disorders of cognition. In: Racagni G Brunello N Langer SZ editors. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Int Acad Biomed Drug Res Basel Karger 1994; 7 : 89\u2013 93."},{"key":"e_1_2_1_37_1","doi-asserted-by":"crossref","unstructured":"Richardson BP Engel G Donatsch P Stadler PA. Identifica-tion of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316 :126.","DOI":"10.1038\/316126a0"},{"key":"e_1_2_1_38_1","doi-asserted-by":"crossref","unstructured":"Giordano J Rogers LV. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 1989; 170 :83\u2013 6.","DOI":"10.1016\/0014-2999(89)90137-4"},{"key":"e_1_2_1_39_1","doi-asserted-by":"crossref","unstructured":"Giordano J Daleo C Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur J Pharmacol 1998; 354 :13\u2013 4.","DOI":"10.1016\/S0014-2999(98)00492-0"},{"key":"e_1_2_1_40_1","doi-asserted-by":"crossref","unstructured":"Saria A Javorsky F Humpel C Gamse R. 5-HT3-receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990; 1 :104\u2013 6.","DOI":"10.1097\/00001756-199010000-00005"},{"key":"e_1_2_1_41_1","doi-asserted-by":"crossref","unstructured":"Ambesh SP Dubey PK Sinha PK et al. Ondansetron pretreatment to alleviate pain on propofol injection: a randomized controlled double-blinded study. Anesth Analg 1999; 89 :197\u2013 9.","DOI":"10.1213\/00000539-199907000-00035"},{"key":"e_1_2_1_42_1","doi-asserted-by":"crossref","unstructured":"Muller C Pongratz S Pidlich J et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron. Eur J Gastroenterol Hepatol 1998; 10 :865\u2013 70.","DOI":"10.1097\/00042737-199810000-00010"},{"key":"e_1_2_1_43_1","doi-asserted-by":"crossref","unstructured":"Ebersberger A Anton F Tolle TR et al. Morphine 5-HT2 and 5-HT3 receptor antagonists reduce c-fos expression in the trigeminal nuclear complex following noxious chemi-chal stimulation of the rat nasal mucosa. Brain Res 1995; 676 :336\u2013 42.","DOI":"10.1016\/0006-8993(95)00118-A"},{"key":"e_1_2_1_44_1","doi-asserted-by":"crossref","unstructured":"Moore KA Taylor GE Weinreich D. Serotonin unmasks functional NK-2 receptors in vagal sensory neurones of the guinea-pig. J Physiol 1999; 514: 111\u2013 24.","DOI":"10.1111\/j.1469-7793.1999.111af.x"},{"key":"e_1_2_1_45_1","doi-asserted-by":"crossref","unstructured":"Ali Z Wu G Kozlov A et al. The role of 5-HT3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. Neuroscience Letters 1996; 208 :203\u2013 7.","DOI":"10.1016\/0304-3940(95)12600-7"},{"key":"e_1_2_1_46_1","doi-asserted-by":"crossref","unstructured":"Alhaider AA Lei SZ Wilcox GL. Spinal 5-HT3-mediated anti-nociception - possible release of GABA. J Neurosci 1991; 11: 1881\u2013 8.","DOI":"10.1523\/JNEUROSCI.11-07-01881.1991"},{"key":"e_1_2_1_47_1","doi-asserted-by":"crossref","unstructured":"Glaum SR Proudfit HK Anderson EG. Reversal of the antinociceptive effects of intrathecally administered serotonin in the rat by a selective antagonist. Neurosci Lett 1988; 95 :313\u2013 7.","DOI":"10.1016\/0304-3940(88)90677-5"},{"key":"e_1_2_1_48_1","doi-asserted-by":"crossref","unstructured":"Tagaki J Yonehara N. Serotonin receptor subtypes involved in modulation of electrical acupuncture. Jpn J Pharmacol 1998; 78 :511\u2013 4.","DOI":"10.1254\/jjp.78.511"},{"key":"e_1_2_1_49_1","doi-asserted-by":"crossref","unstructured":"Pelissier T Alloui A Paeile C et al. Evidence of a central antinociceptive effect of paracetamol involving spinal 5-HT3 receptors. NeuroReport 1995; 6 :1546\u2013 8.","DOI":"10.1097\/00001756-199507310-00020"},{"key":"e_1_2_1_50_1","doi-asserted-by":"crossref","unstructured":"Faris PL Kim SW Meller WH et al. Effect of ondansetron a 5-HT3 receptor antagonist on the dynamic association between bulimic behaviors and pain thresholds. Pain 1998; 77 :297\u2013 303.","DOI":"10.1016\/S0304-3959(98)00108-0"},{"key":"e_1_2_1_51_1","doi-asserted-by":"crossref","unstructured":"Sorensen J Bengtsson A Backman E et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine lidocaine and ketamine. Scand J Rheumatol 1995; 24 :360\u2013 5.","DOI":"10.3109\/03009749509095181"}],"container-title":["Scandinavian Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/030097400446625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:12:14Z","timestamp":1713352334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/030097400446625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":50,"journal-issue":{"issue":"sup113","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1080\/030097400446625"],"URL":"https:\/\/doi.org\/10.1080\/030097400446625","relation":{},"ISSN":["0300-9742","1502-7732"],"issn-type":[{"value":"0300-9742","type":"print"},{"value":"1502-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}